FLNA in HCC Patients
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- NCT03081637
- Lead Sponsor
- University of Milan
- Brief Summary
The risk of recurrence after hepatectomy for hepatocellular carcinoma (HCC) is very high. Having a predictive marker of early recurrence (ER) would be desirable to personalize the follow-up and possibly develop new targeted therapy. The aim of this study was to test the expression of Filamin A (FLNA) in a cohort of patients operated for HCC.
- Detailed Description
A consecutive cohort of resected HCC patients will be analyzed. Several different prognostic factors, including FLNA expression, will be tested against the risk of ER. FLNA expression will be analyzed with immunohistochemistry in the intra-tumoral and extra-tumoral tissue compartments using a dedicated tissue microarray.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 115
- The inclusion criteria were represented by the histological positivity for HCC with complete clinical, surgical, pathological, and follow-up data.
- Patients preoperatively treated with chemotherapy or trans-arterial therapy were excluded.
- Similarly, patients operated for recurrent HCC or with non-radical surgery or with missing data were excluded.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of expression of Filamin A (FLNA) in HCC specimens from patients resected for HCC. 2 years after surgery as a minimum follow-up The rate of expression of FLNA in HCC specimens will be measured using standard immunohistochemistry methodology on surgical specimens. Such expression rate will be correlated to several different clinical and pathological parameters.
- Secondary Outcome Measures
Name Time Method